These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11547057)

  • 41. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma.
    Zhao J; Hu J; Cai J; Yang X; Yang Z
    Chin Med J (Engl); 2003 May; 116(5):772-6. PubMed ID: 12875699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
    Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
    Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
    Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
    Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
    Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
    Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.
    Andius P; Johansson SL; Holmäng S
    Urology; 2007 Oct; 70(4):758-62. PubMed ID: 17991551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
    Wu Y; Saldana L; Chillar R; Vadgama JV
    Int J Oncol; 2002 Mar; 20(3):509-16. PubMed ID: 11836562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer.
    Aoki S; Yamada Y; Nakamura K; Taki T; Tobiume M; Honda N
    Oncol Rep; 2006 Aug; 16(2):279-84. PubMed ID: 16820903
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum interleukin-8 and insulin like growth factor-1 in Egyptian bladder cancer patients.
    Mahmoud MA; Ali MH; Hassoba HM; Elhadidy GS
    Cancer Biomark; 2010; 6(2):105-10. PubMed ID: 20571236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma.
    Eder IE; Stenzl A; Hobisch A; Cronauer MV; Bartsch G; Klocker H
    J Urol; 1996 Sep; 156(3):953-7. PubMed ID: 8709371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monocyte tissue factor levels in cancer patients.
    Lwaleed BA; Francis JL; Chisholm M
    Saudi Med J; 2000 Aug; 21(8):722-9. PubMed ID: 11423883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prostate involvement as prognostic factor in patients with superficial bladder tumors.
    Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova JL; Almenar S
    J Urol; 1995 Nov; 154(5):1710-3. PubMed ID: 7563328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential.
    Gravas S; Bosinakou I; Kehayas P; Giannopoulos A
    Urol Int; 2004; 73(2):173-7. PubMed ID: 15331904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.
    Szarvas T; Jäger T; Laszlo V; Kramer G; Klingler HC; vom Dorp F; Romics I; Ergün S; Rübben H
    Urology; 2012 Sep; 80(3):737.e13-8. PubMed ID: 22607948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer.
    Miyake H; Hara I; Yamanaka K; Gohji K; Arakawa S; Kamidono S
    Urology; 1999 Feb; 53(2):302-7. PubMed ID: 9933044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer.
    Szarvas T; Jäger T; Droste F; Becker M; Kovalszky I; Romics I; Ergün S; Rübben H
    Pathol Oncol Res; 2009 Jun; 15(2):193-201. PubMed ID: 18807212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.